Optimization of the cut-offs in acetylcholine receptor antibodies and diagnostic performance in myasthenia gravis patients

被引:6
|
作者
Shao, Kai [1 ]
Yue, Yao-Xian [2 ]
Zhao, Li-Ming [3 ]
Hao, Hong-Jun [4 ]
Ding, Xiao-Jun [5 ]
Jiang, Ping [6 ]
Yan, Chuan-Zhu [1 ,2 ]
Li, Hai-Feng [2 ,6 ]
机构
[1] Shandong Univ, Qilu Hosp Qingdao, Cheeloo Coll Med, Dept Cent Lab, Qingdao, Peoples R China
[2] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Neurol, Jinan, Peoples R China
[3] Linyi Peoples Hosp, Dept Nucl Med, Linyi, Peoples R China
[4] Peking Univ First Hosp, Lab Neuroimmunol, Beijing, Peoples R China
[5] Shandong Univ, Qilu Hosp Qingdao, Cheeloo Coll Med, Dept Neurol, Qingdao, Peoples R China
[6] Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
Acetylcholine receptor antibody; Cut; -off; Myasthenia gravis; Diagnostic performance; Agreement; OPTICA SPECTRUM DISORDER; ASSAY; AUTOANTIBODIES; TITERS;
D O I
10.1016/j.cca.2022.06.017
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objective: This study aims to establish an optimization procedure to define the cut-offs of quantitative assays for acetylcholine receptor antibody (AChRAb), evaluate their diagnostic performance in myasthenia gravis (MG), and explore the association with clinical features. Methods: Samples from a representative cohort of 77 MG patients, 80 healthy controls (HC) and 80 other autoimmune diseases (OAD) patients were tested using competitive inhibition ELISA and RIA. Raw values (OD and cpm) and processed values (inhibition rate, binding rate and concentration) were used to define the cut-offs with statistical methods, a rough method, and receiver operating characteristic (ROC) curve. Optimal cut-offs were selected by comparing false positive rates in HC and OAD individuals. The diagnostic performance was evaluated in whole MG cohort and subgroups. Agreement between ELISA and RIA for AChRAb positivity were examined with Kappa test and McNemar test. Clinical association with AChRAb was explored by comparison among subgroups and with Spearman rank correlation. Results: The optimal cut-offs for AChRAb positivity were determined as OD <= 1.79 for ELISA and cpm > 1234.12 for RIA, which derived from statistical method and performed better than those derived from ROC curves. The sensitivity and specificity were 74.03%, 100% for ELISA, and 74.03%, 99.37% for RIA. There was good agreement between ELISA and RIA for AChRAb positivity in whole cohort and subgroups (weighted k > 0.71, p < 0.01; McNemar test, p > 0.05). Levels of AChRAb were different in MG subgroups (p < 0.01). Correlation between Quantitative Myasthenia Gravis scores and AChRAb levels was moderate for ELISA and RIA (rs = -0.60 and 0.57, p < 0.01). Conclusion: The raw testing values of ELISA and RIA were found as optimal quantitative measures of AChRAb levels. There are good agreements on diagnostic performance between two assays. Quantitative values are more informative than positivity in association with clinical features.
引用
收藏
页码:122 / 130
页数:9
相关论文
共 50 条
  • [21] Acetylcholine receptor antibodies in myasthenia gravis are associated with greater risk of diabetes and thyroid disease
    Toth, C.
    McDonald, D.
    Oger, J.
    Brownell, K.
    ACTA NEUROLOGICA SCANDINAVICA, 2006, 114 (02): : 124 - 132
  • [22] Brainstem Encephalitis With Low-Titer Acetylcholine Receptor Antibodies Mimicking Myasthenia Gravis
    Ayzenberg, Ilya
    Ellrichmann, Gisa
    Schroeder, Christoph
    Toenges, Lars
    Klasing, Anja
    Pappa, Vaia
    Bruck, Wolfgang
    Gold, Ralf
    FRONTIERS IN NEUROLOGY, 2019, 10
  • [23] Detection of antibodies directed against the cytoplasmic region of the human acetylcholine receptor in sera from myasthenia gravis patients
    Tzartos, SJ
    Remoundos, M
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1999, 116 (01) : 146 - 152
  • [24] DOUBLE SEROPOSITIVE MYASTHENIA GRAVIS WITH ACETYLCHOLINE RECEPTOR AND LIPOPROTEIN RECEPTOR-RELATED PROTEIN 4 ANTIBODIES
    Tsivgoulis, Georgios
    Dervenoulas, Georgios
    Tzartos, Socrates J.
    Zompola, Christina
    Papageorgiou, Sokratis G.
    Voumvourakis, Konstantinos
    MUSCLE & NERVE, 2014, 49 (06) : 930 - 931
  • [25] Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis
    Cruz, Pedro M. Rodriguez
    Al-Hajjar, Michal
    Huda, Saif
    Jacobson, Leslie
    Woodhall, Mark
    Jayawant, Sandeep
    Buckley, Camilla
    Hilton-Jones, David
    Beeson, David
    Vincent, Angela
    Leite, Maria Isabel
    Palace, Jacqueline
    JAMA NEUROLOGY, 2015, 72 (06) : 642 - 649
  • [26] DEMONSTRATION OF ACETYLCHOLINE-RECEPTOR ANTIBODIES IN THE SERUM OF MYASTHENIA-GRAVIS PATIENTS APPLYING AFFINITY CHROMATOGRAPHICALLY PURIFIED HUMAN ACETYLCHOLINE-RECEPTOR PREPARATIONS
    KALIES, I
    KALDEN, JR
    HEINZ, F
    JANZEN, RWC
    LACHENMAYER, L
    KLINISCHE WOCHENSCHRIFT, 1979, 57 (17): : 875 - 881
  • [27] Modified radioimmunoassay versus ELISA to quantify anti-acetylcholine receptor antibodies in a mouse model of myasthenia gravis
    Mariscal, Anais
    Martinez, Carmen
    Goethals, Lea
    Cortes-Vicente, Elena
    Molto, Elisabeth
    Juarez, Candido
    Barneda-Zahonero, Bruna
    Querol, Luis
    Le Panse, Rozen
    Gallardo, Eduard
    JOURNAL OF IMMUNOLOGICAL METHODS, 2024, 534
  • [28] Cancer in myasthenia gravis subtypes in relation to immunosuppressive treatment and acetylcholine receptor antibodies: A Swedish nationwide register study
    Verwijst, Johanna
    Westerberg, Elisabet
    Punga, Anna Rostedt
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (05) : 1706 - 1715
  • [29] Clinical and scientific aspects of acetylcholine receptor myasthenia gravis
    Keijzers, Marlies
    Nogales-Gadea, Gisela
    de Baets, Marc
    CURRENT OPINION IN NEUROLOGY, 2014, 27 (05) : 552 - 557
  • [30] Factors predicting remission in thymectomized patients with acetylcholine receptor antibody-positive myasthenia gravis
    Kim, Hyunjin
    Lim, Young-Min
    Lee, Eun-Jae
    Oh, Yeo Jin
    Kim, Kwang-Kuk
    MUSCLE & NERVE, 2018, 58 (06) : 796 - 800